← boardnext 2026-09-30next 2026-10-05next 2026-11-23next 2026-11-30next 2026-12next 2027-01-10next 2027-02next 2027-04-07next 2027-05-26next 2027-05-31next 2027-06-30next 2027-07-02next 2027-07-15next 2027-11-16next 2027-11-26next 2028-01-09next 2028-05-12next 2028-12-01next 2030-06next 2031-09-30next 2036-11-30
BMY
Celgenedistress 0/10 · well-funded / low risk$60.96+0%today-2% from 52w high
Oncology 1
Lead: Lymphoma · est. market ~$18B (approx, global)
Revenue
$11489M
Liquidity
$9745M
Runway
—
Shares 1y
+0%
Price & events
+13.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.3%
1D
+0.7%
1W
+11.0%
1M
+4.5%
3M
+14.0%
6M
+30.4%
1Y
+55.6%
2Y
+9.5%
5Y
+23.7%
All
Overview
- Market Cap
- $124.48B
- Enterprise Value
- $157.06B
- Volume
- 415.64K
- 52 Week Range
- $42.60 – $62.37
- Total Shares
- 2.04B
- Float Shares
- 2.04B
- Short %
- 1.99%
- % Held by Insiders
- 0.08%
- % Held by Institutions
- 83.77%
- RVOL
- 0.04x
- Beta
- 0.23
Pipeline stages · 21 programs
Oral repotrectinib (TPX-0005)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
KarXT
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Golcadomide, Rituximab, Cyclophosphamide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
CC-92480, Bortezomib, Dexamethasone
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
RYZ101
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
mezigdomide, Pomalidomide, Bortezomib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
RYZ401
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
CC-99282, Rituximab, Obinutuzumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
BMS-986353, Fludarabine Phosphate, Cyclophosphamide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Elranatamab, Mezigdomide, Dexamethasone
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Show all 21 programs · 11 more ▾
Arlocabtagene Autoleucel
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
ACE-536
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
CC-97540, Fludarabine, Cyclophosphamide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Dexamethasone, Daratumumab, Bortezomib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
JCAR017 (lisocabtagene maraleucel), ibrutinib, venetoclax
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Rituximab, Methotrexate, Procarbazine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Luspatercept
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
CC-220, Rituximab, Cyclophosphamide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
RYZ801
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Fludarabine, Cyclophosphamide, JCAR017
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Gene-modified (GM) T cell therapy
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 39 trials · 38 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-09-30 Estimated 50% readout ~2026-11-14 | Phase 1/2 | Oral repotrectinib (TPX-0005) | Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma, Primary CNS Tumors | — | recruiting |
| 2026-10-05 Estimated 50% readout ~2026-12-19 | Phase 3 | KarXT | Psychosis Associated With Alzheimer's Disease | — | recruiting |
| 2026-11-23 Estimated 50% readout ~2027-01-07 | Phase 2 | Golcadomide, Rituximab, Cyclophosphamide | Lymphoma, Follicular | — | active not recruiting |
| 2026-11-24 Estimated 50% readout ~2027-02-07 | Phase 3 | KarXT | Alzheimer Disease | — | recruiting |
| 2026-11-30 Estimated 50% readout ~2027-01-14 | Phase 1/2 | CC-92480, Bortezomib, Dexamethasone | Multiple Myeloma | — | active not recruiting |
Show all 39 trials · 34 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12 Estimated 50% readout ~2027-02-14 | Phase 3 | RYZ101, Everolimus, Sunitinib | GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET | — | recruiting |
| 2026-12-09 Estimated 50% readout ~2027-02-22 | Phase 3 | KarXT | Psychosis Associated With Alzheimer's Disease | — | recruiting |
| 2027-01-10 Estimated 50% readout ~2027-03-26 | Phase 3 | mezigdomide, Pomalidomide, Bortezomib | Relapsed or Refractory Multiple Myeloma | — | recruiting |
| 2027-02 Estimated 50% readout ~2027-03-03 | Phase 1 | RYZ401 | GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET, Solid Tumor, Somatostatin Receptor | — | recruiting |
| 2027-04-07 Estimated 50% readout ~2027-05-22 | Phase 1/2 | CC-99282, Rituximab, Obinutuzumab | Lymphoma, Non-Hodgkin | — | active not recruiting |
| 2027-05-26 Estimated 50% readout ~2027-07-10 | Phase 2 | BMS-986368 | Multiple Sclerosis Spasticity | — | recruiting |
| 2027-05-31 Estimated 50% readout ~2027-07-15 | Phase 1/2 | Elranatamab, Mezigdomide, Dexamethasone | Multiple Myeloma | — | recruiting |
| 2027-06-30 Estimated 50% readout ~2027-08-14 | Phase 2 | Arlocabtagene Autoleucel | Multiple Myeloma | — | recruiting |
| 2027-07 Estimated 50% readout ~2027-07-31 | Phase 1 | RYZ101 Dose Level 1, RYZ101 Dose Level 2, RYZ101 Dose Level 3 | SCLC,Extensive Stage | — | active not recruiting |
| 2027-07-02 Estimated 50% readout ~2027-08-16 | Phase 2 | ACE-536 | Beta-Thalassemia | — | recruiting |
| 2027-07-15 Estimated 50% readout ~2027-08-14 | Phase 1 | CC-97540, Fludarabine, Cyclophosphamide | Multiple Sclerosis, Myasthenia Gravis | — | recruiting |
| 2027-09-07 Estimated 50% readout ~2027-11-21 | Phase 3 | KarXT | Psychosis Associated With Alzheimer's Disease | — | recruiting |
| 2027-09-12 Estimated 50% readout ~2027-11-26 | Phase 3 | BMS-986365, Enzalutamide, Abiraterone | Metastatic Castration-resistant Prostate Cancer | — | recruiting |
| 2027-11-16 Estimated 50% readout ~2028-01-30 | Phase 3 | Dexamethasone, Daratumumab, Bortezomib | Multiple Myeloma | — | active not recruiting |
| 2027-11-26 Estimated 50% readout ~2028-01-10 | Phase 2 | BMS-986368 | Agitation, Alzheimer Disease | — | recruiting |
| 2027-11-26 Estimated 50% readout ~2028-01-10 | Phase 1/2 | JCAR017 (lisocabtagene maraleucel), ibrutinib, venetoclax | Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic | — | recruiting |
| 2027-12-30 Estimated 50% readout ~2028-03-14 | Phase 3 | BMS-986393, Cyclophosphamide, Fludarabine | Relapsed or Refractory Multiple Myeloma (RRMM) | — | recruiting |
| 2028-01-09 Estimated 50% readout ~2028-02-23 | Phase 2 | Rituximab, Methotrexate, Procarbazine | Lymphoma | — | recruiting |
| 2028-02-29 Estimated 50% readout ~2028-04-14 | Phase 1/2 | Oral repotrectinib (TPX-0005) | Locally Advanced Solid Tumors, Metastatic Solid Tumors | — | recruiting |
| 2028-04-24 Estimated 50% readout ~2028-07-08 | Phase 3 | Golcadomide, Rituximab, Lenalidomide | Follicular Lymphoma | — | recruiting |
| 2028-05-12 Estimated 50% readout ~2028-07-26 | Phase 3 | Luspatercept | Myelodysplastic Syndromes (MDS), Beta-thalassemia, Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis | — | recruiting |
| 2028-05-17 Estimated 50% readout ~2028-07-01 | Phase 2 | CC-97540, Fludarabine, Cyclophosphamide | Lupus Erythematosus, Systemic, Lupus Nephritis | — | recruiting |
| 2028-08-01 Estimated 50% readout ~2028-08-31 | Phase 1 | BMS-986393, Alnuctamab, Mezigdomide | Multiple Myeloma | — | recruiting |
| 2028-08-14 Estimated 50% readout ~2028-10-28 | Phase 3 | Golcadomide, Rituximab, Cyclophosphamide | Large B-cell Lymphoma | — | active not recruiting |
| 2028-10 Estimated 50% readout ~2028-11-15 | Phase 1/2 | RYZ101 | Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer | — | active not recruiting |
| 2028-11-14 Estimated 50% readout ~2029-01-28 | Phase 3 | BMS-986353, Fludarabine, Cyclophosphamide | Systemic Sclerosis | — | recruiting |
| 2028-12-01 Estimated 50% readout ~2028-12-31 | Phase 1 | CC-220, Rituximab, Cyclophosphamide | Lymphoma, B-Cell | — | recruiting |
| 2030-03-08 Estimated 50% readout ~2030-05-22 | Phase 3 | KarXT | Schizophrenia, Autism-Related Irritability | — | recruiting |
| 2030-05-02 Estimated 50% readout ~2030-06-01 | Phase 1 | BMS-986453, Fludarabine, Cyclophosphamide | Relapsed and/or Refractory Multiple Myeloma | — | recruiting |
| 2030-05-06 Estimated 50% readout ~2030-06-20 | Phase 2 | BMS-986353, Fludarabine Phosphate, Cyclophosphamide | Chronic Immune Thrombocytopenia, Autoimmune Hemolytic Anemia | — | not yet recruiting |
| 2030-06 Estimated 50% readout ~2030-07-16 | Phase 1/2 | RYZ801 | Hepatocellular Carcinoma (HCC) | — | recruiting |
| 2031-09-30 Estimated 50% readout ~2031-11-14 | Phase 2 | Fludarabine, Cyclophosphamide, JCAR017 | Lymphoma, Non-Hodgkin | — | active not recruiting |
| 2036-11-30 Estimated 50% readout ~2037-02-13 | Phase 2/3 | Gene-modified (GM) T cell therapy | Neoplasms | — | recruiting |
| 2026-07-18 Estimated 50% readout ~2026-10-01 final ~2027-09-30 | Phase 3 | Mezigdomide, Carfilzomib, Dexamethasone | Relapsed or Refractory Multiple Myeloma | — | active not recruiting |
Catalyst news & presentations · 28
- 2028Guided 40%readoutPumitamig · ROSETTA-Lung-012 NME registrational data expected in 2028SEC 8-K
- 2028Guided 40%readoutZola-cel · Breakfree-SLE NME registrational data expected in 2028SEC 8-K
- 2028Guided 40%readoutArlo-cel · QUINTESSENTIAL-2 LCM pivotal data expected in 2028SEC 8-K
- 2028Guided 40%readoutCobenfy · ADAGIO-2 LCM pivotal data expected in 2028SEC 8-K
- 2028Guided 40%readoutKrazati · KRYSTAL-7 LCM pivotal data expected in 2028SEC 8-K
- 2028Guided 40%readoutAtigotatug + nivolumab · TIGOS NME registrational data expected in 2028SEC 8-K
- 2028Guided 40%readoutGolcadomide · GOLSEEK-1 NME registrational data expected in 2028SEC 8-K
- 2028Guided 40%readoutIza-bren · IZABRIGHT-Breast01 NME registrational data expected in 2028SEC 8-K
- 2027Guided 40%readoutAR LDD mCRPC · rechARge data expected in 2027SEC 8-K
- 2027Guided 40%readoutReblozyl · ELEMENT LCM pivotal data expected in 2027SEC 8-K
- 2027Guided 40%readoutSotyktu · POETYK SjS-1 LCM pivotal data expected in 2027SEC 8-K
- 2027Guided 40%readoutCobenfy · BALSAM-1 & 2 LCM pivotal data expected in 2027SEC 8-K
- 2027Guided 40%readoutAdmilparant · ALOFT-PPF LCM pivotal data expected in 2027SEC 8-K
- 2027Guided 40%readoutMezigdomide · SUCCESSOR-1 LCM pivotal data expected in 2027SEC 8-K
- 2026Guided 40%readoutCobenfy · ADEPT-1,2,4 data expected in 2026SEC 8-K
- 2026Guided 40%readoutSotyktu · POETYK SLE-1 & 2 data expected in 2026SEC 8-K
- 2026Guided 40%readoutMYK-224 · AURORA early-stage data expected in 2026SEC 8-K
- 2026Guided 40%readoutPumitamig · Early-stage data expected in 2026 (trial by BioNTech)SEC 8-K
- 2026Guided 40%readoutZola-cel · Breakfree-1 & 2 early-stage data expected in 2026SEC 8-K
- 2026Guided 40%readoutRYZ101 · ACTION-1 data expected in 2026SEC 8-K
- 2026Guided 40%readoutBCMAxGPRC5D dual-targeting CAR T · Early-stage data expected in 2026SEC 8-K
- 2026Guided 40%readoutArlo-cel · QUINTESSENTIAL topline data expected in 2026SEC 8-K
- 2026Guided 40%readoutMezigdomide · SUCCESSOR-2 data expected in 2026SEC 8-K
- 2026Guided 40%readoutMilvexian · LIBREXIA-AF1 data expected in 2026SEC 8-K
- 2026Guided 40%readoutAdmilparant · ALOFT-IPF topline data expected in 2026SEC 8-K
- 2026Guided 40%readoutGolcadomide · GOLSEEK-2 early-stage data expected in 2026SEC 8-K
- 2026Guided 40%readoutIberdomide · EXCALIBER-RRMM PFS data expected in 2026SEC 8-K
- 2026-07-30Confirmed 100%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 2,042,071,247 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $63 (+3% upside) · 24 analysts
- 2026-07-10B of A SecuritiesBuy
- 2026-07-06Cantor FitzgeraldNeutral
- 2026-04-09B of A SecuritiesBuy
- 2026-04-08Cantor FitzgeraldNeutral
- 2026-04-08GuggenheimBuy
- 2026-03-17HSBCHold
Competitors — Lymphoma
- LLYELI LILLY & Co$1094.4B · D3
- ABBVAbbVie Inc.$451.1B · D2
- MRKMerck & Co., Inc.$318.8B · D3
- REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2
- BEIGFBeOne Medicines Ltd.$31.7B · D1
- NRIXNurix Therapeutics, Inc.$2.4B · D6
- ALLOAllogene Therapeutics, Inc.$623M · D5
- ADILADIAL PHARMACEUTICALS, INC.$6M · D6
- GMABGENMAB A/S— · D1
- AZNASTRAZENECA PLC— · D3
Recent news
- 2026-07-22DOL Takes Swipe At Derisking Cases In Bristol-Myers Brief - Law360
- 2026-07-22Donald Trump - BRISTOL MYERS SQUIBB CO Trump Trade on May. 18, 2026 - Quiver Quantitative
- 2026-07-21Bristol Myers Squibb Supercharges Drug Discovery With NVIDIA AI - Sahm
- 2026-07-21Bristol Myers Squibb stock trades steady as oncology pipeline and recent results frame investor focu - Ad-hoc-news.de
- 2026-07-21Bristol Myers Squibb (BMY) Expands AI Capabilities with Nvidia S - GuruFocus
- 2026-07-20Bristol Myers Squibb (BMY) Expands AI Capabilities with Nvidia S - GuruFocus
- 2026-07-20Bristol Myers buys Nvidia's latest AI computing system for drug research - Reuters
- 2026-07-20Bristol Myers Squibb Supercharges Drug Discovery With NVIDIA AI - Benzinga
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.